Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06423326 | Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 2 | 36 | Georgetown UniversityOTHER | 1 | Sep 30, 2026 |
| clinicaltrials |
| NCT06492954 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma(AflacST2301) | recruiting | Phase 1 | 12 | Emory UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06510530 | Astragalus for Symptomatic Alleviation in High-grade Lymphoma | not yet recruiting | Phase 3 | 60 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06515249 | Integrative Therapies in Multiple Myeloma | recruiting | N/A | 300 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06541405 | Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia | terminated | Early Phase 1 | 2 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06541444 | Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Early Phase 1 | 2 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06565052 | The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06630429 | A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06630780 | Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma(REPORT-HNSCC) | active not recruiting | N/A | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06674863 | Addressing Health Literacy With a Tailored Survivorship Care Plan | recruiting | N/A | 150 | Emory UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06750458 | Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | completed | Phase 3 | 75 | Tanta UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer(rechARge) | active not recruiting | Phase 3 | 960 | CelgeneINDUSTRY | 26 | Sep 30, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Sep 30, 2026 | clinicaltrials |
| NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | recruiting | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 30, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06826014 | TREC@TAMU Cancer Prevention Registry and Repository | recruiting | — | 2,500 | Texas A&M UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 42 | IpsenINDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT06855628 | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) | completed | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06890273 | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)(DUOLife) | recruiting | — | 150 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06918002 | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients(ElLen) | recruiting | Phase 3 | 824 | Intergroupe Francophone du MyelomeNETWORK | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06990698 | A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 108 | Zhuhai Fapon Biopharma Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 65 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07023887 | Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning(EXERT-BCHC) | recruiting | — | 15 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | recruiting | Phase 1 | 170 | ALX Oncology Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07137793 | Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients(PTX / BC) | completed | Phase 2 | 46 | Tanta UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07218250 | A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07224035 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 | completed | Phase 4 | 430 | University of MiamiOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07224048 | Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2 | completed | Phase 4 | 50 | University of MiamiOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07231952 | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07287111 | Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound | completed | N/A | 797 | BeamWorks Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07342114 | A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 240 | Genentech, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 32 | Sep 30, 2026 | clinicaltrials |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | recruiting | Phase 3 | 750 | Bristol-Myers SquibbINDUSTRY | 36 | Sep 30, 2026 | clinicaltrials |
| NCT07378670 | DEfeating PEnile CAncer-2(DEPECA-2) | recruiting | N/A | 80 | University Hospital TuebingenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07410169 | Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy | recruiting | Phase 2 / Phase 3 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07415135 | Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy | completed | Phase 2 | 18 | Zhu YinjieOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07437950 | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 126 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT07465172 | GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer(GRADE) | not yet recruiting | N/A | 150 | Breast Cancer Trials, Australia and New ZealandOTHER | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)(ALISCA-Lung2) | recruiting | Phase 2 | 50 | Puma Biotechnology, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303) | recruiting | Phase 3 | 900 | Revolution Medicines, Inc.INDUSTRY | 12 | Sep 30, 2026 | clinicaltrials |
Data updated yesterdaySource updated Sep 30, 2026source: clinicaltrials